Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05537662
NA

External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes (XANADO)

Sponsor: Abbott Medical Devices

View on ClinicalTrials.gov

Summary

This is a prospective, longitudinal, single-center, non-randomized, open-label, post-market clinical feasibility study to assess the efficacy of neuromodulation therapies (SCS and DRG) for chronic pain patients with diabetes and investigate whether physical and physiological data collected from diabetic and pre-diabetic chronic pain patients is predictive of subjective patient-reported outcomes (PROs) and of adjustments in patient care. These assessments will be made prior to, during, and after the trial of the SCS or DRG system. The study will be carried out in the United States at a single site.

Official title: External Sensing and Neuromodulation to Assess Diabetic Pain Outcomes

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2023-06-06

Completion Date

2025-04

Last Updated

2024-07-12

Healthy Volunteers

No

Conditions

Interventions

DEVICE

Standard of care neuromodulation therapy (SCS or DRG)

Standard SCS or DRG therapy

Locations (1)

Rush University Medical Center

Chicago, Illinois, United States